Posts for Ticker ‘BMRN’

Top 10 Analyst Upgrades, Downgrades, Initiations (MT, BMRN, ELN, FITB, FSLR, GCI, GT, HAL, PVTB, URBN)

These are this Thursday morning’s top 10 analyst upgrades, downgrades, and initiations we have seen in early research calls from Wall Street:

ArcelorMittal (NYSE: MT) Raised to Buy at Societe Generale.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Raised to Outperform at Credit Suisse.
Elan Corp. plc (NYSE: ELN) Cut to Neutral at UBS.
Fifth Third Bancorp Raised To Outperform From Neutral By Baird
First Solar Inc. (NASDAQ: FSLR) Cut to Neutral at BofA/Merrill.
Gannett Co. (NYSE: GCI) Cut to Underperform at Wells Fargo.
Goodyear Tire (NYSE: GT) Cut to Underperform at BofA/Merrill.
Halliburton Co. (NYSE: HAL) Started as Outperform at Wells Fargo.
PrivateBancorp Inc. (NASDAQ: PVTB) Cut to Neutral at JPMorgan.
Urban Outfitters (NASDAQ: URBN) Raised to Overweight at Thomas Weisel.

You can join our open email distribution list to get updates on top analyst upgrades and downgrades, top day trader alerts, IPO’s, secondary offerings, Warren Buffett and other guru activity, M&A and more.

JON C. OGG

Posted on: October 29, 2009 – 7:45 am in Analyst Calls, , , , , , , , , ,

BioHealth Business Daily (BMRN, DVAX, SEPR, STEM, PCYC, OCLS)

biotech imageToday is an unusually active day for many emerging biotech stocks in the news and we are seeing significant moves in response. We have more detail on each with appropriate links through to more analysis and data at BioHealthInvestor.com or VSInvestor.com:

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is seeing exponential trading volume in stock and options after a 10% rise today.

Dynavax Technologies Corporation (NASDAQ: DVAX) is up over 50%after the FDA removed a clinical hold on its hepatitis treatment.

The fight over the Sepracor, Inc. (NASDAQ: SEPR) acquisition has now gone to the level of a class action status.  We noted the very low P/E and multiple valuations yesterday on this one.

StemCells, Inc. (NASDAQ: STEM) traded slightly higher on word that it will soon begin a study with the University of California, San Francisco Children’s Hospital using purified human neural stem cells as a possible treatment for Pelizaeus-Merzbacher Disease.

Pharmacyclics Inc. (NASDAQ: PCYC) was trading up on news that its right offering is oversubscribed.

Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) is trading higher on report that it has been assigned a Medicare HCPCS code for its recently introduced Microcyn Skin & Wound HydroGel.

JON C. OGG
SEPTEMBER 10, 2009

Posted on: September 10, 2009 – 1:38 pm in Biotech, Drug companies, HI/LOW, Trading Alert, , , , , ,

Top 10 Analyst Upgrades & Downgrades (ALTR, XLNX, BMRN, FWLT, PALM, VRTX, EIX, MGM, POM, TIF)

These are the top 10 analyst calls we have seen this Wednesday morning with about two hours until the market opens:

  • Altera (ALTR) and Xilinx (XLNX) Raised to Overweight at Global Crown.
  • Biomarin Pharma    (BMRN) Raised to Buy at Citigroup.
  • Foster Wheeler (FWLT) Raised to Buy at Jefferies.
  • Palm (PALM) Raised to Buy at Piper Jaffray.
  • Vertex Pharm (VRTX) Raised to Accumulate at ThinkEquity.
  • Edison (EIX) Cut to Market Perform at Wachovia.
  • MGM Mirage (MGM) Cut to Hold at KeyBanc.
  • Pepco Holdings (POM) was downgraded at both Barclays and at Wachovia.
  • Tiffany (TIF) target cut by over 60% to $21.00 at HSBC.

JON C. OGG
March 4, 2009

Posted on: March 4, 2009 – 7:53 am in Analyst Calls, , , , , , , , , ,

Top Pre-Market Analyst Downgrades (ACGY, BMRN, CTCM, DENN, XOM, LF, OXY)

burning-money-pic14These are some of the top early bird Analyst Downgrades seen from Wall Street analysts this Thursday morning:

  • Acergy (ACGY) Cut to Sell at Citigroup.
  • BioMarin Pharmaceutical (BMRN) downgraded at Citigroup, Collins Stewart, and Wachovia.
  • CTC Media (CTCM) Cut To Market Weight from Overweight at Thomas Weisel.
  • Denny’s (DENN) Cut to Neutral at Merriman Curhan Ford.
  • Exxon Mobil (XOM) Cut to Market Perform at Bernstein; Cut to Equal Weight at Barclays.
  • LeapFrog (LF) Cut to Neutral at Piper Jaffray.
  • Occidental Petroleum (OXY) Cut to Underperform at Bernstein.

Jon C. Ogg
February 19, 2009

Posted on: February 19, 2009 – 7:37 am in Analyst Calls, , , , , , ,

La Jolla Gets More Hope (LJPC, BMRN)

Money_stack_pic_5La Jolla Pharmaceutical Company (NASDAQ: LJPC) has been more than just a troubled biotech.  It has even been considered an at-risk entity by some traders after it had been down more than 90% at one point, but the company may have just gotten a much needed lifeline. 

It has signed a development and commercialization pact with BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) for its Riquent®.  This is La Jolla’s investigational drug for lupus nephritis, a candidate being evaluated in a Phase 3 clinical study for orphan disease Lupus Nephritis.  Under the terms of the agreement, BioMarin will receive a co-exclusive license to develop and commercialize Riquent.  La Jolla could receive up to $289 million in cash if everything materializes properly.

Full details of the pact are available at BioHealthInvestor.com.

Jon C. Ogg
January 6, 2009

Posted on: January 6, 2009 – 5:01 pm in Biotech, ,

Top Pre-Market Analyst Upgrades (ARMH, BMRN, CYBX, FFIV, GPS, JNPR, LTD, MSFT, MYGN, NVTL, CRM)

These are the top pre-market analyst upgrades and positive calls we are seeing from Wall Street firms this Friday morning with more than two hours until the open.

  • Arm Holdings (ARMH) Raised to Buy at Goldman Sachs.
  • Biomarin Pharma (BMRN) Raised to Buy at Citigroup.
  • Cyberonics (CYBX) Raised to Buy at PiperJaffray
  • F5 Networks (FFIV) Started as Outperform at William Blair.
  • Gap Inc. (GPS) Raised to Buy at Citigroup.
  • Juniper Networks (JNPR) Started as Outperform at William Blair.
  • Limited (LTD)  Raised to Buy at Citigroup.
  • Microsoft (MSFT) Raised to Outperform at Oppenheimer.
  • Myriad Genetics (MYGN) Raised to Buy at Citigroup.
  • Novatel Wireless (NVTL) Raised to Neutral from Sell at Piper Jaffray.
  • Salesforce.com (CRM) Raised to Outperform at Baird.

Jon C. Ogg
November 21, 2008

Posted on: November 21, 2008 – 7:33 am in Analyst Calls, , , , , , , , , , ,

Biotech Business Daily (BTRX, BMRN, DSCO, ENDP, MNKD, MIPI, QSC, TECH)

Today almost feels like the "March of Biotech-inguins" because most of the movers were small companies you might otherwise miss.  Here were the big movers:

  • Barrier Therapeutics (NASDAQ: BTRX) ran way up after first quarter results reported yesterday showed a 207% increase in revenues from last year at $8.4 million, driven by growth in sales of Vusion and Xolegel. Shares closed up 18% at $2.29 on a 52-week range of $1.90 to $7.60.
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) showed a first quarter positive profit or $0.02 EPS on a net income of $1.7 million. Analysts expected losses of $0.05 EPS. Earnings were driven primarily by sales of enzyme replacement therapy Naglazyme. Shares closed up almost 8% at $36.46. The 52-week range is $15.99 to $41.00.
  • Discovery Labs (NASDAQ: DSCO) trading up in anticipation of FDA approval for lung surfactant, Surfaxin, a treatment for premature infants suffering from respiratory distress. The company communicated confidence that any regulatory concerns have been ironed out and this third FDA result will be positive. Shares rose 17% to $2.87. The 52-week range is $1.75 to $3.75.
  • Endo Pharmaceuticals (NASDAQ: ENDP) settled a proxy battle with shareholder D.E. Shaw by nominating William Spangler to the board. They posted earnings today showing a net income of $59.53 and $0.44 EPS. Shares closed down 0.7% at $24.83. The 52-week range is $22.62 to $35.85.
  • Mannkind Corporation (NASDAQ: MNKD) up over 16% in anticipation of earnings release Monday. Shares up $0.37 at $2.60 at the close. The 52-week range is $1.86 to $14.71.
  • Molecular Insight Pharma (NASDAQ: MIPI) up almost 7% today on no news, although some just may be the thin volume and wide bid/ask spread. The oncology molecular imaging pharmaceutical company is sitting at $7.83 on a 52-week range of $5.66 to $12.95.
  • Questcor (AMEX: QSC) down despite posting strong first quarter results showing a positive net income of $6.5 million compared to a loss of $3.8 in first quarter 2007. The company also amended agreement Acthar distribution discount prices, positively impacting Questcor cash flows. Shares closed down 2.5% at $4.24. The 52-week range is $0.21 to $6.60.
  • Techne Corp. (NASDAQ: TECH) up after third quarter profit jumped 24% to $29.6 million or $0.76 EPS, beating estimates. Shares closed at $72.52, up 1%, on a 52-week range of $54.49 to $72.00.

Rachel Lopez
April 30, 2008

Posted on: April 30, 2008 – 3:21 pm in Biotech, Newsletter, , , , , , , ,

Cramer Buy, Sell, Hold Calls For 2008 On His 2007 Picks (GS, MO, HAL, CSCO, AAPL, NYX, BMRN, RAD, LVLT)

On tonight’s MAD MONEY on CNBC, Jim Cramer came out and wanted to give his BUY, SELL, or HOLD recommendations on his Top 9 Picks from 2007 now that we are into 2008.  He already gave some of this commentary in the segments before this, but these were consolidated all at once as a summary for his opinion ahead into 2008.  Here are his recommendations below:

VALUE PICKS:

  • Goldman Sachs (NYSE: GS)….This is a good stock but in a bad neighborhood. He doesn’t expect much appreciation, at least not immediately or until later in 2008 after the FOMC comes to the rescue of financials.
  • Altria (NYSE: MO)… This is his favorite of these ahead of International spin-off.  will get to buy back stock after the legal issue is behind it.  We have this one under screen for our own Special Situation Investing Newsletter.
  • Halliburton (NYSE: HAL) should work again but he thinks it is more of a nat-gas play.2.  GROWTH PICKS:

GROWTH PICKS:

  • Cisco Systems (NASDAQ:CSCO)…He’s worn out on it and thinks it may just be a marginal performer. Prefers Hewlett-Packard (HPQ)
  • Apple (NASDAQ:AAPL)… He’s sticking with because of that 30% earnings growth and compared it to the New England Patriots; although he doesn’t expect last year’s performance to be a repeat.
  • NYSE Euronext (NYSE: NYX)… Cramer thinks it is having a great quarter and may have a great year.  He thinks you can buy it and hang on for the ride up.  Thinks estimates are too low.

SPECULATIVE PICKS:

  • BioMarin (NASDAQ:BMRN) should still work and he thinks numbers are far too low with a great pipeline.
  • Rite Aid (NYSE: RAD)… Despite CEO coming on the show and owning up to the problems it is having, he cannot bless RAD until he sees a couple good quarters.  We just noted this as a turnaround that is having trouble turning around.
  • Level 3 Communications (NASDAQ:LVLT)… He wants to stick with it now that the CEO is back in charge after a life threatening illness.  This one appears in screens for our own "10 Stocks Under $10" weekly newsletter and we just noted how this has fallen enough that it could double this year under the right circumstances.

As Cramer noted that the market is too wishy washy right now, he’s not coming out with any year-end picks nor is he coming out with formal targets.  We did compile a master list of some of the top Cramer calls from 2007 that we felt will still be pertinent into 2008.

Jon C. Ogg
January 2, 2008

Join our free email distribution list that covers some Cramer picks and that shows previews for IPO’s, spin-offs, break-ups, merger-arb, and more.

Posted on: January 2, 2008 – 7:20 pm in Cramer, , , , , , , , ,

Cramer Reviews 2007 Into 2008 (AUY, ABX, BMRN, HAL, AAPL, MO, SVNT, RIMM, GOOG, AMZN, RAD, LVLT, NYX, CSCO)

On tonight’s MAD MONEY on CNBC, Jim Cramer kicked off 2008 by being somewhat cautious on the volatility in 2008.  Cramer said he wants to Add gold to the portfolio  with Barrick Gold (NYSE: ABX) for speculative gold and Yamana (NYSE:AUY) growth gold.  Cramer did review TOP 9 PICKS FOR 2007 and showed that if you contain your losses you can make money since the 9 picks he said were up 16% collectively.  He wants to contain losses and let the winners win:

  • Apple (NASDAQ:AAPL) is one he wants to stick with.  Halliburton (NYSE:HAL) is another one he wants to stick with as well as it underperformed the sector.  Altria (NYSE:MO) beat the averages and he likes the management there.
  • Rite Aid (NYSE:RAD) was a horrible loser with -53% and Level 3 Communications (NASDAQ:LVLT) was down by -49%, but they did both rise substantially before rising.  Both had bad balance sheets and that was an omen he won’t try to repeat.Goldman Sachs (NYSE:GS) as a company only rose 8% because of the financial stocks, despite that it won in the entire group.  NYSE Euronext (NYSE: NYX) was the worst one with a horrible loss.  Cheap technology companies don’t work and that ended up being the case with Cisco Systems (NASDAQ: CSCO). 
  • Cramer said that the market is just too fickle to make year-end predictions in companies.  So with an election and a crazy market he is not going to play that game.

Cramer did say that BIOTECH is the sector to speculate in during 2008, although he notes that with large rewards you can expect large risk.  He noted that his pick of Savient (NASDAQ:SVNT) and then the trade out into BioMarin (NASDAQ:BMRN) turned more than a 70% gainer there.

If you want to see our consolidated summary with our top Cramer coverage with all of his various lists of 2007 stocks that are being updated in the coming days you can see that here.  This morning he said that he sees agriculture and solar continuing to win, and his best sector for 2008 was just listed as oil & gas.  He also said he wouldn’t be a seller of Apple (NASDAQ:AAPL) because of the 30% earnings growth that only a handful of companies have; he’s still positive on three of his Four Horsemen of Tech Research-in-Motion (NASDAQ:RIMM) and Google (NASDAQ:GOOG), although he’d sell Amazon.com (NASDAQ:AMZN) above $100.00.

Jon C. Ogg
January 2, 2008

Posted on: January 2, 2008 – 6:27 pm in Cramer, , , , , , , , , , , , , ,

Pre-Market Analyst Calls (November 6, 2007)

Stock Tickers: ANF, ARO, AEO, ANN, ADSK, BMRN, CA, CHS, C, COGN, CWTR, ETR, GPS, GOOG, JCG, LF, MA, MSFT, ORH, ORCL, PAS, PNWIF, PT, RIMM, JAVA, SYMC, UA, URBN

Abercrombie & Fitch (ANF) started as Buy at UBS.
Aeropostale (ARO) started as Neutral at UBS.
American Eagle Outfitters (AEO) raised to Hold at Citigroup.
Ann Taylor (ANN) started as Buy at UBS.
Autodesk (ADSK) raised to Overweight at Lehman.
Biomarin (BMRN) Started as Buy at Jefferies.
CA INC. (CA) raised to Equal-Weight at Lehman.
Chico’s FAS (CHS) started as Neutral at UBS.
Citigroup (C) cut to Neutral at B of A.
Cognos (COGN) cut to Sector Perform at CIBC.
Coldwater Creek (CWTR) started as Neutral at UBS.
Entergy (ETR) cut to Hold at Jefferies.
Gap Inc. (GPS) started as Buy at UBS.
Googe (GOOG) target raised to $850 at Sanford Bernstein.
J.Crew (JCG) started as Neutral at UBS.
Leapfrog (LF) started as Strong Buy at Needham.
MasterCard (MA) raised to Buy at Deutsche Bank.
Microsoft (MSFT) removed from Conviction Buy List at Goldman Sachs.
OdysseyRe (ORH) raised to Hold at Citigroup.
Oracle (ORCL) replaced Microsoft on Goldman Sachs Conviction Buy List.
PepsiAmericas (PAS) cut to Underweight at JPMorgan.
PhotoChannel (PNWIF) started as Buy at Merriman Curhan Ford.
Portugal Telecom (PT) raised to Buy at UBS.
Research In Motion (RIMM) raised to Outperform at Credit Suisse.
Sun Micro (JAVA) raised to Buy at Citigroup.
Symantec (SYMC) cut to Equal-Weight at Lehman.
Under Armour (UA) started as Underweight at Morgan Stanley.
Urban Outfitters (URBN) started as Buy at UBS.

Jon C. Ogg
November 6, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: November 6, 2007 – 7:57 am in Analyst Calls, , , , , , , , , , , , , , , , , , , , , , , , , , , ,